CL2019001136A1 - Inmunoglobulinas y usos de estas. - Google Patents

Inmunoglobulinas y usos de estas.

Info

Publication number
CL2019001136A1
CL2019001136A1 CL2019001136A CL2019001136A CL2019001136A1 CL 2019001136 A1 CL2019001136 A1 CL 2019001136A1 CL 2019001136 A CL2019001136 A CL 2019001136A CL 2019001136 A CL2019001136 A CL 2019001136A CL 2019001136 A1 CL2019001136 A1 CL 2019001136A1
Authority
CL
Chile
Prior art keywords
immunoglobulins
platform
subject
methods
pharmaceutical compositions
Prior art date
Application number
CL2019001136A
Other languages
English (en)
Inventor
Ellen Chi
Rui Zhang
Mark Macielag
Raymond J Patch
Mark Wall
Yue-Mei Zhang
Martin A Case
Shamina M Rangwala
James N Leonard
Raul C Camacho
Michael J Hunter
Katharine E D´Aquino
Wilson Edwards
Wenying Jian
Ronald V Swanson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2019001136A1 publication Critical patent/CL2019001136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON UNA PLATAFORMA DE ANTICUERPOS MONOCLONALES DISEÑADA PARA ACOPLARSE A PÉPTIDOS TERAPÉUTICOS PARA AUMENTAR LA VIDA MEDIA DEL PÉPTIDO TERAPÉUTICO EN UN SUJETO. LA INVENCIÓN SE RELACIONA TAMBIÉN CON COMPOSICIONES FARMACÉUTICAS Y CON MÉTODOS PARA USARLAS.
CL2019001136A 2016-10-27 2019-04-25 Inmunoglobulinas y usos de estas. CL2019001136A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413586P 2016-10-27 2016-10-27
US201662413613P 2016-10-27 2016-10-27

Publications (1)

Publication Number Publication Date
CL2019001136A1 true CL2019001136A1 (es) 2019-07-05

Family

ID=62020814

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019001110A CL2019001110A1 (es) 2016-10-27 2019-04-23 Compuestos del péptido tirosina tirosina cíclico como moduladores de receptores de neuropéptido y.
CL2019001129A CL2019001129A1 (es) 2016-10-27 2019-04-24 Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
CL2019001136A CL2019001136A1 (es) 2016-10-27 2019-04-25 Inmunoglobulinas y usos de estas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2019001110A CL2019001110A1 (es) 2016-10-27 2019-04-23 Compuestos del péptido tirosina tirosina cíclico como moduladores de receptores de neuropéptido y.
CL2019001129A CL2019001129A1 (es) 2016-10-27 2019-04-24 Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.

Country Status (37)

Country Link
US (14) US10640544B2 (es)
EP (4) EP3534928A4 (es)
JP (6) JP7387431B2 (es)
KR (6) KR102653376B1 (es)
CN (3) CN110099692B (es)
AU (5) AU2017348180A1 (es)
BR (3) BR112019008351A2 (es)
CA (3) CA3041674A1 (es)
CL (3) CL2019001110A1 (es)
CO (3) CO2019003938A2 (es)
CR (3) CR20190210A (es)
CY (1) CY1124732T1 (es)
DK (1) DK3532486T3 (es)
DO (3) DOP2019000106A (es)
EC (3) ECSP19029942A (es)
ES (1) ES2897480T3 (es)
HR (1) HRP20211626T1 (es)
HU (1) HUE056442T2 (es)
IL (4) IL266202B2 (es)
JO (3) JOP20190095A1 (es)
LT (1) LT3532486T (es)
MA (3) MA46672A (es)
MD (1) MD3532486T2 (es)
MX (4) MX2019004955A (es)
NI (2) NI201900043A (es)
PE (3) PE20190916A1 (es)
PH (3) PH12019500723A1 (es)
PL (1) PL3532486T3 (es)
PT (1) PT3532486T (es)
RS (1) RS62677B1 (es)
SA (3) SA519401647B1 (es)
SG (4) SG10202107777XA (es)
SI (1) SI3532486T1 (es)
TW (4) TWI781118B (es)
UY (3) UY37457A (es)
WO (3) WO2018081367A1 (es)
ZA (1) ZA202200648B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW202014433A (zh) * 2018-04-25 2020-04-16 比利時商健生藥品公司 類升糖素肽１（ｇｌｐ－１）融合肽偶合環狀酪酪肽接合物及其用途
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
JPWO2020262590A1 (es) * 2019-06-28 2020-12-30
JP2023500895A (ja) 2019-11-11 2023-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎｐｙ２受容体アゴニスト
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
PE20231566A1 (es) 2020-08-07 2023-10-04 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
CN115073556A (zh) * 2021-03-12 2022-09-20 上海天慈生命科学发展有限公司 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用
KR20240054261A (ko) * 2021-06-14 2024-04-25 다르빅스 엘엘씨 개선된 약리학적 및 약물 전달 특성을 갖는 glp-1 수용체 작용제
WO2023097363A1 (en) * 2021-11-30 2023-06-08 Garvan Institute Of Medical Research Improved binding proteins and uses thereof
CN115028551B (zh) * 2022-07-15 2024-01-05 成都普康生物科技有限公司 一种叠氮-九甘醇-丙酸的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2434149A1 (fr) 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
US5393669A (en) 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007109354A2 (en) * 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2008060783A2 (en) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
SG171957A1 (en) 2008-11-04 2011-07-28 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
MX2011004427A (es) * 2008-11-05 2011-05-31 Hoffmann La Roche Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos.
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
US8906649B2 (en) * 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
US8394378B2 (en) * 2010-09-27 2013-03-12 Janssen Biotech, Inc. Antibodies binding human collagen II
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
DK2668212T3 (en) * 2011-01-28 2018-07-02 Saonofi Biotechnology HUMAN ANTIBODIES AGAINST PCSK9 FOR USE IN PROCEDURES FOR TREATING PARTICULAR GROUPS OF PERSONS
TWI601744B (zh) * 2011-06-17 2017-10-11 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
CN104080811B (zh) 2011-11-04 2019-09-27 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2871112C (en) 2012-07-04 2020-05-12 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
PL2916819T3 (pl) 2012-11-06 2020-01-31 Hanmi Pharm. Co., Ltd. Płynna formuła koniugatu białka zawierająca oksyntomodulinę i fragment immunoglobulinowy
CA2896248A1 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2014110368A1 (en) 2013-01-11 2014-07-17 The California Institute For Biomedical Research Bovine fusion antibodies
US20160108098A1 (en) 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
WO2015157595A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112017001789A2 (pt) 2014-07-30 2018-07-24 Ngm Biopharmaceuticals, Inc. composições e métodos de uso para tratamento de distúrbios metabólicos
MX2018005545A (es) 2015-11-02 2019-02-20 Janssen Pharmaceutica Nv Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estas.
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW202014433A (zh) * 2018-04-25 2020-04-16 比利時商健生藥品公司 類升糖素肽１（ｇｌｐ－１）融合肽偶合環狀酪酪肽接合物及其用途

Also Published As

Publication number Publication date
EP3532486A1 (en) 2019-09-04
DOP2019000178A (es) 2020-02-16
DOP2019000106A (es) 2019-09-30
JP2019534283A (ja) 2019-11-28
AU2017348172B2 (en) 2021-10-07
KR20190072615A (ko) 2019-06-25
EP3532092A1 (en) 2019-09-04
US10968264B2 (en) 2021-04-06
EP3532486B8 (en) 2022-01-12
RS62677B1 (sr) 2021-12-31
SA519401646B1 (ar) 2021-12-26
EP3988123A1 (en) 2022-04-27
JP7090077B2 (ja) 2022-06-23
CA3041674A1 (en) 2018-05-03
EP3532092A4 (en) 2020-07-01
JOP20190096A1 (ar) 2019-04-28
TW201827456A (zh) 2018-08-01
JOP20190096B1 (ar) 2023-09-17
PL3532486T3 (pl) 2022-01-31
JP2022137031A (ja) 2022-09-21
US20190345214A1 (en) 2019-11-14
US10640544B2 (en) 2020-05-05
US10968265B2 (en) 2021-04-06
HRP20211626T1 (hr) 2022-02-04
UY37457A (es) 2018-04-30
US20180125998A1 (en) 2018-05-10
AU2021269420B2 (en) 2023-11-23
US10428134B2 (en) 2019-10-01
KR20190073492A (ko) 2019-06-26
CA3041046A1 (en) 2018-05-03
WO2018081370A1 (en) 2018-05-03
MX2023005465A (es) 2023-05-22
BR112019008500A2 (pt) 2019-07-09
TWI794189B (zh) 2023-03-01
CA3041672A1 (en) 2018-05-03
MA46665A (fr) 2019-09-04
US20200385439A1 (en) 2020-12-10
CR20190209A (es) 2019-08-21
MA46718A (fr) 2019-09-11
EP3532486B1 (en) 2021-09-22
TW202304972A (zh) 2023-02-01
KR20240046290A (ko) 2024-04-08
PH12019500906A1 (en) 2020-01-20
HUE056442T2 (hu) 2022-02-28
SA519401647B1 (ar) 2022-01-26
US20210163566A1 (en) 2021-06-03
US10858413B2 (en) 2020-12-08
CR20190208A (es) 2019-05-27
JP2019534281A (ja) 2019-11-28
CR20190210A (es) 2019-05-27
PH12019500723A1 (en) 2019-11-11
US20240018208A1 (en) 2024-01-18
TWI781118B (zh) 2022-10-21
US20210094998A1 (en) 2021-04-01
US20190263879A1 (en) 2019-08-29
US11591379B2 (en) 2023-02-28
JP7387431B2 (ja) 2023-11-28
KR102653376B1 (ko) 2024-04-02
CY1124732T1 (el) 2022-07-22
WO2018081367A1 (en) 2018-05-03
AU2017348180A1 (en) 2019-04-18
CN110036022A (zh) 2019-07-19
KR20230129194A (ko) 2023-09-06
PH12019500749A1 (en) 2019-11-11
JOP20190097A1 (ar) 2019-04-28
IL266202A (en) 2019-06-30
TW201829455A (zh) 2018-08-16
CO2019003938A2 (es) 2019-04-30
ECSP19029995A (es) 2019-05-31
UY37455A (es) 2018-04-30
KR20190072616A (ko) 2019-06-25
JP7231539B2 (ja) 2023-03-01
IL266204A (en) 2019-06-30
LT3532486T (lt) 2021-11-10
JP2020510606A (ja) 2020-04-09
EP3534928A4 (en) 2020-08-12
US11401315B2 (en) 2022-08-02
NI201900043A (es) 2019-10-25
US20190367577A1 (en) 2019-12-05
PE20190916A1 (es) 2019-06-26
CN110099692B (zh) 2024-03-12
AU2017348172A1 (en) 2019-04-18
AU2021269420A1 (en) 2021-12-16
ECSP19029942A (es) 2019-05-31
TW201827081A (zh) 2018-08-01
SG10202107777XA (en) 2021-08-30
AU2022200089A1 (en) 2022-02-03
NI201900044A (es) 2019-09-09
CO2019004186A2 (es) 2019-05-10
MA46665B1 (fr) 2021-09-30
AU2017348175B2 (en) 2021-08-26
US11732019B2 (en) 2023-08-22
PE20190917A1 (es) 2019-06-26
SG11201902879SA (en) 2019-05-30
CO2019004203A2 (es) 2019-05-10
US11767354B2 (en) 2023-09-26
US20180117170A1 (en) 2018-05-03
ZA202200648B (en) 2024-02-28
KR102653381B1 (ko) 2024-04-02
ES2897480T3 (es) 2022-03-01
JP2024020405A (ja) 2024-02-14
SA519401642B1 (ar) 2022-03-07
AU2017348175A1 (en) 2019-04-18
IL266202B2 (en) 2023-09-01
JOP20190095A1 (ar) 2019-04-28
US20180127476A1 (en) 2018-05-10
ECSP19029835A (es) 2019-05-31
CN110099692A (zh) 2019-08-06
US10787495B2 (en) 2020-09-29
BR112019008417A2 (pt) 2019-09-03
KR20240046621A (ko) 2024-04-09
US20230365644A1 (en) 2023-11-16
IL266206A (en) 2019-06-30
PT3532486T (pt) 2021-11-19
PE20191079A1 (es) 2019-08-20
SG11201902873RA (en) 2019-05-30
DK3532486T3 (da) 2021-10-18
BR112019008351A2 (pt) 2019-10-01
MD3532486T2 (ro) 2022-01-31
IL301843A (en) 2023-06-01
US20190298849A1 (en) 2019-10-03
AU2022200089B2 (en) 2023-11-16
US20200283491A1 (en) 2020-09-10
EP3532486A4 (en) 2020-06-24
US10961293B2 (en) 2021-03-30
TWI773699B (zh) 2022-08-11
JP2023012467A (ja) 2023-01-25
WO2018081375A1 (en) 2018-05-03
MX2019004955A (es) 2019-06-24
IL266202B1 (en) 2023-05-01
UY37456A (es) 2018-04-30
MX2019004952A (es) 2019-06-24
SI3532486T1 (sl) 2021-12-31
KR102573684B1 (ko) 2023-09-04
MA46672A (fr) 2019-09-04
CL2019001129A1 (es) 2019-07-05
SG11201902886SA (en) 2019-05-30
CL2019001110A1 (es) 2019-07-05
EP3534928A1 (en) 2019-09-11
CN109890410A (zh) 2019-06-14
DOP2019000107A (es) 2019-09-30
MX2019004954A (es) 2019-06-24
US20210206822A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
CL2019001136A1 (es) Inmunoglobulinas y usos de estas.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
UY35964A (es) Anticuerpos humanos para pd?1
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
CR20180519A (es) Neoantígenos y métodos de su uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201892294A1 (ru) Антитела и композиции против tim-3
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CR20190271A (es) Anticuerpos antitau y métodos de uso
EA201691974A1 (ru) Антитела против ox40 и способы их применения
BR112016023948A2 (pt) proteínas fc multiméricas
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
UY36021A (es) Proteìnas fc multimèricas
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
CY1121895T1 (el) Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19
MA49122A (fr) Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
BR112017012381A2 (pt) imunoterapia para doença angiogênica
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний